Principal Financial Group Inc. Sells 12,411 Shares of Alexion Pharmaceuticals, Inc. (ALXN)
Principal Financial Group Inc. lessened its holdings in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 3.7% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 323,114 shares of the biopharmaceutical company’s stock after selling 12,411 shares during the quarter. Principal Financial Group Inc. owned 0.14% of Alexion Pharmaceuticals worth $45,330,000 as of its most recent SEC filing.
Several other institutional investors have also made changes to their positions in ALXN. Dimensional Fund Advisors LP boosted its position in shares of Alexion Pharmaceuticals by 4.4% in the first quarter. Dimensional Fund Advisors LP now owns 321,459 shares of the biopharmaceutical company’s stock valued at $38,975,000 after acquiring an additional 13,679 shares during the period. Oregon Public Employees Retirement Fund raised its stake in Alexion Pharmaceuticals by 0.9% in the second quarter. Oregon Public Employees Retirement Fund now owns 23,624 shares of the biopharmaceutical company’s stock valued at $2,874,000 after purchasing an additional 200 shares in the last quarter. CrestPoint Capital Management LLC acquired a new position in Alexion Pharmaceuticals in the second quarter valued at about $487,000. LS Investment Advisors LLC raised its stake in Alexion Pharmaceuticals by 6.6% in the second quarter. LS Investment Advisors LLC now owns 6,533 shares of the biopharmaceutical company’s stock valued at $795,000 after purchasing an additional 402 shares in the last quarter. Finally, Louisiana State Employees Retirement System raised its stake in Alexion Pharmaceuticals by 0.7% in the second quarter. Louisiana State Employees Retirement System now owns 13,900 shares of the biopharmaceutical company’s stock valued at $1,691,000 after purchasing an additional 100 shares in the last quarter. 96.71% of the stock is owned by institutional investors.
Shares of Alexion Pharmaceuticals, Inc. (ALXN) opened at $110.34 on Thursday. Alexion Pharmaceuticals, Inc. has a twelve month low of $96.18 and a twelve month high of $149.34. The company has a market capitalization of $24,570.59, a P/E ratio of 22.49, a P/E/G ratio of 1.20 and a beta of 1.22. The company has a quick ratio of 2.51, a current ratio of 2.96 and a debt-to-equity ratio of 0.35.
Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.44 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.32 by $0.12. Alexion Pharmaceuticals had a return on equity of 12.55% and a net margin of 14.57%. The business had revenue of $859.00 million for the quarter, compared to analysts’ expectations of $864.34 million. During the same period in the prior year, the business posted $1.23 earnings per share. The firm’s revenue was up 7.5% on a year-over-year basis. equities analysts predict that Alexion Pharmaceuticals, Inc. will post 4.81 EPS for the current fiscal year.
ALXN has been the subject of a number of analyst reports. BidaskClub raised Alexion Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, July 25th. Morgan Stanley reaffirmed an “overweight” rating and issued a $153.00 price target (up previously from $141.00) on shares of Alexion Pharmaceuticals in a research note on Friday, July 28th. Oppenheimer Holdings, Inc. raised Alexion Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $175.00 price target for the company in a research note on Friday, July 28th. Leerink Swann boosted their price target on Alexion Pharmaceuticals from $136.00 to $170.00 and gave the company an “outperform” rating in a research note on Friday, July 28th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and issued a $168.00 price target (up previously from $159.00) on shares of Alexion Pharmaceuticals in a research note on Friday, July 28th. Six analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $154.01.
ILLEGAL ACTIVITY WARNING: This article was first published by Watch List News and is owned by of Watch List News. If you are reading this article on another website, it was illegally stolen and reposted in violation of international trademark & copyright laws. The legal version of this article can be accessed at https://www.watchlistnews.com/principal-financial-group-inc-sells-12411-shares-of-alexion-pharmaceuticals-inc-alxn/1706898.html.
In related news, Director Ann M. Veneman sold 835 shares of the company’s stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $145.81, for a total value of $121,751.35. Following the sale, the director now directly owns 5,480 shares in the company, valued at $799,038.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Julie O’neill sold 11,160 shares of the company’s stock in a transaction that occurred on Monday, August 28th. The shares were sold at an average price of $140.00, for a total value of $1,562,400.00. Following the completion of the sale, the executive vice president now owns 26,704 shares in the company, valued at $3,738,560. The disclosure for this sale can be found here. Insiders sold 16,490 shares of company stock worth $2,337,251 over the last quarter. 4.35% of the stock is currently owned by company insiders.
Alexion Pharmaceuticals Profile
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.